99 participants
Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2024-10-08
- Start Date:
- 2022-02-01
- Completion:
- 2023-01-01
Conditions
- Metastatic Renal Cell Carcinoma
No Results Yet